Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 2/2013

01-02-2013 | Article

Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy

Authors: C. D. Andersen, L. Bennet, L. Nyström, U. Lindblad, E. Lindholm, L. Groop, O. Rolandsson

Published in: Diabetologia | Issue 2/2013

Login to get access

Abstract

Aims/hypothesis

Our aim was to study whether glycaemic control differs between individuals with latent autoimmune diabetes in adults (LADA) and patients with type 2 diabetes, and whether it is influenced by time on insulin therapy.

Methods

We performed a retrospective study of 372 patients with LADA (205 men and 167 women; median age 54 years, range 35–80 years) from Swedish cohorts from Skåne (n = 272) and Västerbotten (n = 100). Age- and sex-matched patients with type 2 diabetes were included as controls. Data on the use of oral hypoglycaemic agents (OHAs), insulin and insulin–OHA combination therapy was retrieved from the medical records. Poor glycaemic control was defined as HbA1c ≥7.0% (≥53 mmol/mol) at follow-up.

Results

The individuals with LADA and with type 2 diabetes were followed for an average of 107 months. LADA patients were leaner than type 2 diabetes patients at diagnosis (BMI 27.7 vs 31.0 kg/m2; p < 0.001) and follow-up (BMI 27.9 vs 30.2 kg/m2; p < 0.001). Patients with LADA had been treated with insulin for longer than those with type 2 diabetes (53.3 vs 28.8 months; p < 0.001). There was no significant difference between the patient groups with regard to poor glycaemic control at diagnosis, but more patients with LADA (67.8%) than type 2 diabetes patients (53.0%; p < 0.001) had poor glycaemic control at follow-up. Patients with LADA had worse glycaemic control at follow-up compared with participants with type 2 diabetes (OR = 1.8, 95% CI 1.2, 2.7), adjusted for age at diagnosis, HbA1c, BMI at diagnosis, follow-up time and duration of insulin treatment.

Conclusions/interpretation

Individuals with LADA have worse glycaemic control than patients with type 2 diabetes despite a longer time on insulin therapy.
Literature
1.
Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMedCrossRef
2.
Davis TM, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702PubMedCrossRef
3.
Bakhtadze E, Cervin C, Lindholm E et al (2008) Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15–34 years) but not in middle-aged (40–59 years) diabetic patients. Diabetologia 51:2224–2232PubMedCrossRef
4.
Desai M, Cull CA, Horton VA et al (2007) GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50:2052–2060PubMedCrossRef
5.
Thunander M, Petersson C, Jonzon K et al (2008) Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 82:247–255PubMedCrossRef
6.
Kobayashi T, Nakanishi K, Murase T, Kosaka K (1996) Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622–626PubMedCrossRef
7.
Maruyama T, Tanaka S, Shimada A et al (2008) Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93:2115–2121PubMedCrossRef
8.
Norberg M, Wall S, Boman K, Weinehall L (2010) The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action Mar 22:3
9.
Rolandsson O, Norberg M, Nystrom L et al (2012) How to diagnose and classify diabetes in primary health care: lessons learned from the Diabetes Register in Northern Sweden (DiabNorth). Scand J Prim Health Care 30:81–87PubMedCrossRef
10.
Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
11.
Fourlanos S, Dotta F, Greenbaum CJ et al (2005) Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206–2212PubMedCrossRef
12.
Brophy S, Yderstraede K, Mauricio D et al (2008) Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 31:439–441PubMedCrossRef
13.
Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef
14.
Lindholm E, Hallengren B, Agardh CD (2004) Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases. Diabetes Metab Res Rev 20:158–164PubMedCrossRef
15.
Lundgren VM, Isomaa B, Lyssenko V et al (2010) GAD antibody positivity predicts type 2 diabetes in an adult population. Diabetes 59:416–422PubMedCrossRef
16.
Falorni A, Ortqvist E, Persson B, Lernmark A (1995) Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 186:89–99PubMedCrossRef
17.
Grubin CE, Daniels T, Toivola B et al (1994) A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344–350PubMedCrossRef
18.
Daka B, Svensson MK, Lernmark Å, Mincheva-Nilsson L, Hallmans G, Rolandsson O (2009) Low agreement between radio binding assays in analyzing glutamic acid decarboxylase (GAD65Ab) autoantibodies in patients classified with type 2 diabetes. Autoimmunity 42:1–8CrossRef
19.
20.
Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G (2001) High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 86:3032–3038PubMedCrossRef
21.
Buzzetti R, Di Pietro S, Giaccari A et al (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30:932–938PubMedCrossRef
Metadata
Title
Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy
Authors
C. D. Andersen
L. Bennet
L. Nyström
U. Lindblad
E. Lindholm
L. Groop
O. Rolandsson
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2759-y

Other articles of this Issue 2/2013

Diabetologia 2/2013 Go to the issue

Article

Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes

Commentary

Lipotoxicity impairs incretin signalling

Article

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

Article

Prediction and classification of cardiovascular disease risk in older adults with diabetes

Article

Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes

Article

Human blood outgrowth endothelial cells improve islet survival and function when co-transplanted in a mouse model of diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits